|View printer-friendly version|
Kevin Rakin Appointed to the Histogenics Board of Directors
Waltham, Mass. – November 12, 2012 – Histogenics Corp., a biologics company that combines cell therapy and tissue engineering technologies to develop highly innovative products primarily for orthopaedic tissue repair and regeneration, today announced the appointment of Kevin L. Rakin to its Board of Directors. Mr. Rakin has over 20 years of experience in the biotechnology industry and most recently served as President of Regenerative Medicine at Shire plc.
“We are very pleased to welcome Kevin to the Histogenics Board of Directors. His broad biotechnology and regenerative medicine experience over a 20 year career in the industry will be extremely valuable during this exciting time for the company,” said Patrick O’Donnell, President and Chief Executive Officer of Histogenics. “We believe that his current role as President of Regenerative Medicine at Shire, his experience with the development of regenerative medicine treatments, and his understanding of niche markets, will help us as advance the clinical development program of NeoCart® which is currently enrolling patients in a phase 3 clinical study.”
Kevin Rakin was most recently the President of Regenerative Medicine at Shire plc, a leading specialty biopharmaceutical company. Prior to joining Shire, Mr. Rakin served as the Chairman and CEO of Advanced BioHealing (ABH) from 2007 until its acquisition by Shire for $750 million, in June 2011. Before this, he served at the interim CEO of ABH and executive-in-residence at Canaan Partners. Previously, he was a co-Founder, President & Chief Executive Officer of Genaissance Pharmaceuticals, Inc., a publicly held pharmacogenomics company, until its merger with Clinical Data, Inc. in October 2005. Earlier, he was Genaissance’s President and Chief Financial Officer and was responsible for completing private and public financings in excess of $150 million.
He currently serves on the executive committee for Connecticut United for Research Excellence (CURE), Connecticut’s bioscience cluster. He has previously served as a board member for Ipsogen SA, Vion Pharmaceuticals, Inc., OMRIX Biopharmaceuticals, Inc, and Clinical Data, Inc. Rakin holds an M.B.A. from Columbia University and received his graduate and undergraduate degrees in Commerce from the University of Cape Town, South Africa.
Histogenics is a leading regenerative medicine company that combines cell therapy and tissue engineering technologies to develop highly innovative products for tissue repair and regeneration. In May of 2011, Histogenics acquired Israeli cell-therapy company ProChon BioTech. Histogenics’ flagship products focus on the treatment of active patients suffering from articular cartilage derived pain and immobility. The Company takes an interdisciplinary approach to engineering neocartilage that looks, acts and lasts like hyaline cartilage. It is developing new treatments for sports injuries and other orthopedic conditions, where demand is growing for long-term alternatives to joint replacement. Histogenics has successfully completed Phase 1 and Phase 2 clinical trials in which the NeoCart autologous tissue implant’s effectiveness is compared to that of standard microfracture surgery. Based in Waltham, Massachusetts, the company is privately held. For more information, visit www.histogenics.com.